Inhibitors in Hemophilia B

Abstract

Hemophilia B (HB) is an X-linked bleeding disorder caused by deficiency of factor IX (FIX). Patients with the severe form (FIX <1%) account approximately for 30 to 45% of persons with HB and usually suffer from recurrent joint, soft-tissue, and muscle bleeds. The availability of safe plasma-derived and recombinant products has virtually abolished the risk of viral infections and the adoption of prophylactic regimens has attenuated the impact of hemophilic arthropathy. Therefore, the development of an inhibitor against FIX is currently the most serious complication that can still occur in the new generations of HB patients. The development of an inhibitor in HB is a rare event (1.5–3% of all patients) but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic/anaphylactic reactions and nephrotic syndrome. Due to the relative rarity of this event, few data exist about risk factors, pathophysiology, and clinical aspects of inhibitors in HB. The induction of immune tolerance is often unsuccessful and can be otherwise affected by many complications in patients with history of allergy or anaphylaxis. Therefore, alternative therapeutic strategies and new approaches are developing. The aim of this narrative review is to discuss current knowledge about risk factors, pathophysiology, and clinical aspects of this rare but serious complication.

Keywords

hemophilia B - inhibitor - FIX - bypassing agents - anaphylaxis - nephrotic syndrome - immune tolerance induction

• References

• 1 Castaman G, Bonetti E, Messina M. , et al; Italian Association of Hemophilia Centers. Inhibitors in haemophilia B: the Italian experience. Haemophilia 2013; 19 (05) 686-690
• 2 Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 2015; 13 (07) 1184-1195
• 3 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (05) 1027-1031
• 4 Powell JS, Pasi KJ, Ragni MV. , et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
• 5 Santagostino E, Martinowitz U, Lissitchkov T. , et al; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016; 127 (14) 1761-1769
• 6 Collins PW, Young G, Knobe K. , et al; Paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124 (26) 3880-3886
• 7 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (03) 305-315
• 8 Santagostino E, Fasulo MR. Hemophilia a and hemophilia B: different types of diseases?. Semin Thromb Hemost 2013; 39 (07) 697-701
• 9 Puetz J, Soucie JM, Kempton CL, Monahan PE. ; Hemophilia Treatment Center Network (HTCN) Investigators. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2014; 20 (01) 25-31
• 10 Harper JL, Gill JC, Hopp RJ, Evans J, Haire WD. Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor. Thromb Haemost 1995; 74 (04) 1039-1041
• 11 Warrier I, Ewenstein BM, Koerper MA. , et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19 (01) 23-27
• 12 Thorland EC, Drost JB, Lusher JM. , et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5 (02) 101-105
• 13 Warrier I. Inhibitors in haemophilia B. In: Textbook of Hemophilia. Lee C, Berntorp E, Hoots KW. eds. Oxford: Blackwell Publishers; 2005: 97-100
• 14 Kadar JG, Schuster J, Hunzelmann N. IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia 2007; 13 (01) 104-105
• 15 Ewenstein BM, Takemoto C, Warrier I. , et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89 (03) 1115-1116
• 16 Van Den Berg M, Carcao M, Santagostino E. , et al. On behalf of PedNet study group. Inhibitor incidence in pups with severe haemophilia B is higher than usually reported; data from PedNet registry [abstract]. Haemophilia 2018; 24 (S1): 24
• 17 Briet E. Factor IX inhibitor in hemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coagul Fibrinolysis 1991; 2 (Suppl. 01) 47-50
• 18 Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 (Suppl. 01) 49-52
• 19 Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996; 2 (01) 28-31
• 20 Ljung R, Petrini P, Tengborn L, Sjörin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113 (01) 81-86
• 21 Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127 (04) 379-391
• 22 Franchini M, Santoro C, Coppola A. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review. Thromb Haemost 2016; 116 (01) 201-203
• 23 Rallapalli PM. Factor IX Variant Database. Available at: http://www.factorix.org/ . Accessed January 15, 2018
• 24 Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH. ; Hemophilia Inhibitor Research Study Investigators. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. J Thromb Haemost 2016; 14 (10) 1931-1940
• 25 Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 1974; 26 (01) 129-140
• 26 Carmassi F, Giannarelli C, De Giorgi A, De Negri F. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs. Haemophilia 2007; 13 (01) 106-107
• 27 High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Adv Exp Med Biol 1995; 386: 79-86
• 28 Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2 (07) 1082-1095
• 29 Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother 2005; 6 (09) 1517-1524
• 30 Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013; 11 (07) 1329-1340
• 31 Miller CH, Benson J, Ellingsen D. , et al; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 2012; 18 (03) 375-382
• 32 Radic CP, Rossetti LC, Abelleyro MM. , et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost 2013; 109 (01) 24-33
• 33 Belvini D, Salviato R, Radossi P. , et al; AICE HB Study Group. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005; 90 (05) 635-642
• 34 Saini S, Hamasaki-Katagiri N, Pandey GS. , et al. Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B. Haemophilia 2015; 21 (02) 210-218
• 35 Green P. A Database of Point Mutations and Short Additions and Deletions in the Factor IX Gene. Haemophilia B Mutation Database, King's College London, University of London, London, Version 13; 2004. Available at: http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html . Accessed April 2, 2007
• 36 Chen SH, Zhang M, Lovrien EW, Scott CR, Thompson AR. CG dinucleotide transitions in the factor IX gene account for about half of the point mutations in hemophilia B patients: a Seattle series. Hum Genet 1991; 87 (02) 177-182
• 37 Matsushita T, Tanimoto M, Yamamoto K. , et al. DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene. J Lab Clin Med 1990; 116 (04) 492-497
• 38 Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: a new online resource. Mol Genet Genomic Med 2013; 1 (04) 238-245
• 39 Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. ; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107 (08) 3167-3172
• 40 Astermark J, Oldenburg J, Carlson J. , et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108 (12) 3739-3745
• 41 Lozier JN, Tayebi N, Zhang P. Mapping of genes that control the antibody response to human factor IX in mice. Blood 2005; 105 (03) 1029-1035
• 42 Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17 (03) 494-499
• 43 Franchini M, Lippi G, Montagnana M. , et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis 2009; 20 (04) 225-229
• 44 Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17 (02) 179-184
• 45 Sawamoto Y, Shima M, Yamamoto M. , et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83 (04) 279-286
• 46 Christophe OD, Lenting PJ, Cherel G. , et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. Blood 2001; 98 (05) 1416-1423
• 47 Cugno M, Mancuso ME, Tedeschi A. , et al. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. Haemophilia 2017; 23 (04) e348-e353
• 48 Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol 1998; 102 (01) 113-117
• 49 Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011; 11 (03) 262-268
• 50 Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54 (02) 201-213
• 51 Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132 (01) 13-24
• 52 Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116 (03) 833-841
• 53 Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 2009; 124 (04) 639-646 , quiz 647–648
• 54 Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120 (03) 506-515 , quiz 516–517
• 55 Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A 2011; 108 (30) 12413-12418
• 56 Jönsson F, Mancardi DA, Kita Y. , et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest 2011; 121 (04) 1484-1496
• 57 Warrier I. ITI in hemophilia B: Possibilities and Problems. The International Monitor on Hemophilia. 10-Year Anniversary Issue; 2003:20–23
• 58 Warrier I. Management of hemophilia B patients with inhibitors and anaphylaxis. In: Varon D, Martinowitz U, Heim M. , eds. Haemophilia and Related Disorders. Vol 4. Oxford: Blackwell Science Ltd; 1998: 574-576
• 59 Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol 1998; 12 (08) 654-657
• 60 Warrier I. Factor IX inhibitors and anaphylaxis. In: Rodriguez-Merchan ED, Lee CA. , eds. Inhibitors in Patients with Haemophilia. Oxford: Blackwell Science; 2002: 87-91
• 61 Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15 (01) 320-328
• 62 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 364-371
• 63 Di Michele DM. Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost 2011; 9 (Suppl. 01) 216-225
• 64 Bon A, Morfini M, Dini A. , et al. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review. Ital J Pediatr 2015; 41: 12
• 65 DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159 (02) 123-134
• 66 Collins PW, Chalmers E, Hart DP. , et al; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160 (02) 153-170
• 67 Rocino A, Coppola A, Franchini M. , et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
• 68 DiMichele DM, Kroner BL. ; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87 (01) 52-57
• 69 Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-195
• 70 Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci U S A 1986; 83 (23) 9169-9173
• 71 Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IMT. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999; 5 (01) 32-39
• 72 Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with hemophilia B by simple plasmapheresis and antigen exposure: progress report. Haemophilia 2001; 7: 437-438
• 73 Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 2003; 9 (03) 269-271
• 74 Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30 (01) 93-95
• 75 Curry NS, Misbah SA, Giangrande PL, Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia 2007; 13 (03) 328-330
• 76 Chuansumrit A, Moonsup Y, Sirachainan N, Benjaponpitak S, Suebsangad A, Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis 2008; 19 (03) 208-211
• 77 Batorova A, Morongova A, Tagariello G, Jankovicova D, Prigancova T, Horakova J. Challenges in the management of hemophilia B with inhibitor. Semin Thromb Hemost 2013; 39 (07) 767-771
• 78 Cross DC, Van Der Berg HM. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 2007; 13 (01) 111-114
• 79 Wermes C, von Depka Prondzinski M, Welte K, Sykora KW. New strategy for the treatment of factor IX inhibitors in severe haemophilia B [abstract]. Blood 2000; 96: 267a
• 80 Klarmann D, Martinez Saguer I, Funk MB. , et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14 (01) 44-49
• 81 Franchini M, Mengoli C, Lippi G. , et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14 (05) 903-912
• 82 Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125 (03) 366-368
• 83 Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand?. Br J Haematol 2014; 165 (05) 600-608
• 84 Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F. Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor. Hamostaseologie 2014; 34 (Suppl. 01) S5-S8
• 85 Kobayashi R, Sano H, Suzuki D. , et al. Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor. Blood Coagul Fibrinolysis 2015; 26 (05) 580-582
• 86 Beutel K, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 2009; 29 (02) 155-157
• 87 DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 01) 1-22
• 88 Hilgartner M, Aledort L, Andes A, Gill J. ; FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30 (07) 626-630
• 89 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2 (06) 899-909
• 90 Astermark J, Donfield SM, DiMichele DM. , et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (02) 546-551
• 91 Brown SA. Treatment of inhibitors in hemophilia B. In: Lee C, Berntorp E, Hoots KW. eds. Textbook of Hemophilia. Oxford: Blackwell Publishers; 2005: 101-105
• 92 Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12 (Suppl. 06) 54-61
• 93 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6 (04) E46
• 94 Mariani G, Kroner B. ; Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86 (11) 1186-1193
• 95 Kasper CK. Diagnosis and management of inhibitors to FVIII and IX. An introductory discussion for physicians. Treatment of Hemophilia Monograph Series, no. 34; September 2004. Available at: http://www.wfh.org/publication/files/pdf-1178.pdf . Accessed April 21, 2018
• 96 Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl. 03) 25-32
• 97 Konkle BA, Ebbesen LS, Erhardtsen E. , et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5 (09) 1904-1913
• 98 Leissinger C, Gringeri A, Antmen B. , et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
• 99 Antunes SV, Tangada S, Stasyshyn O. , et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20 (01) 65-72
• 100 Lheriteau E, Davidoff AM, Nathwani AC. Haemophilia gene therapy: progress and challenges. Blood Rev 2015; 29 (05) 321-328
• 101 Nathwani AC, Rosales C, McIntosh J. , et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011; 19 (05) 876-885
• 102 Nathwani AC, Reiss UM, Tuddenham EG. , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
• 103 George LA, Sullivan SK, Giermasz A. , et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017; 377 (23) 2215-2227
• 104 George LA. Hemophilia gene therapy comes of age. Blood Adv 2017; 1 (26) 2591-2599
• 105 Spencer HT, Riley BE, Doering CB. State of the art: gene therapy of haemophilia. Haemophilia 2016; 22 (22) (Suppl. 05) 66-71
• 106 Dobrzynski E, Herzog RW. Tolerance induction by viral in vivo gene transfer. Clin Med Res 2005; 3 (04) 234-240
• 107 Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A 2006; 103 (12) 4592-4597
• 108 Arruda VR, Samelson-Jones BJ. Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost 2016; 14 (06) 1121-1134
• 109 Annoni A, Cantore A, Della Valle P. , et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med 2013; 5 (11) 1684-1697
• 110 Crudele JM, Finn JD, Siner JI. , et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 2015; 125 (10) 1553-1561
• 111 Mingozzi F, Liu YL, Dobrzynski E. , et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111 (09) 1347-1356
• 112 Markusic DM, Hoffman BE, Perrin GQ. , et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 2013; 5 (11) 1698-1709
• 113 Cao O, Loduca PA, Herzog RW. Role of regulatory T cells in tolerance to coagulation factors. J Thromb Haemost 2009; 7 (07) (Suppl. 01) 88-91
• 114 Nayak S, Cao O, Hoffman BE. , et al. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J Thromb Haemost 2009; 7 (09) 1523-1532
• 115 Doering CB, Spencer HT. Replacing bad (F)actors: hemophilia. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 461-467
• 116 Bigger BW, Siapati EK, Mistry A. , et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 2006; 13 (02) 117-126
• 117 Yarovoi HV, Kufrin D, Eslin DE. , et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003; 102 (12) 4006-4013
• 118 Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood 2010; 116 (08) 1235-1243
• 119 Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther 2014; 22 (01) 169-177
• 120 Chowdary P, Lethagen S, Friedrich U. , et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13 (05) 743-754
• 121 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost 2016; 42 (05) 526-532
• 122 Sehgal A, Barros S, Ivanciu L. , et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (05) 492-497
• 123 Golor G, Bensen-Kennedy D, Haffner S. , et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J Thromb Haemost 2013; 11 (11) 1977-1985
• 124 Gale AJ, Bhat V, Pellequer JL, Griffin JH, Mosnier LO, Von Drygalski A. Safety, stability and pharmacokinetic properties of (super)factor Va, a novel engineered coagulation factor V for treatment of severe bleeding. Pharm Res 2016; 33 (06) 1517-1526
• 125 Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman DD, Arkin S. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa^I16L). J Thromb Haemost 2017; 15 (05) 931-937
• 126 Rea CJ, Foley JH, Sørensen B. Factor XIII in the treatment of hemophilia A. N Engl J Med 2012; 366 (03) 281-283
• 127 Shinkoda Y, Shirahata A, Fukutake K. , et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia 2017; 23 (01) 59-66
• 128 Oldenburg J, Mahlangu JN, Kim B. , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 808-818
• 129 Pasi KJ, Rangarajan S, Georgiev P. , et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377 (09) 819-828
• 130 FDA Lifts Clinical Hold on Fitusiran. Available at: http://investors.alnylam.com/news-releases/news-release-details/fda-lifts-clinical-hold-fitusiran . Accessed January 19, 2018